Literature DB >> 6502479

Drug permeation through human skin II: Permeability of ionizable compounds.

J Swarbrick, G Lee, J Brom, N P Gensmantel.   

Abstract

The aim of this study was to establish whether ionized as well as un-ionized forms of certain 4-oxo-4H-1-benzopyran-2-carboxylic acids (chromone-2-carboxylic acids) with pKa values less than 2 permeated through excised human skin and, if so, to determine the permeability coefficients of the permeating species. The permeation properties of four carboxylic acids were studied as a function of concentration over the pH range 5-7 at 37 degrees C with plexiglass diffusion cells. Plots of J/CA- (the total flux due to un-ionized and ionized species obtained under steady-state conditions per unit concentration of ionized drug in the donor compartment) against CH3O+ resulted in straight-line relationships. The intercepts of these plots were shown to equal PA-, whereas the slopes multiplied by the Ka values of the compounds equalled PHA, the permeability coefficients of the ionized and un-ionized species, respectively. With all four compounds, both species were found to permeate skin, although the permeability coefficients of the un-ionized species were approximately 10(4) greater than those for the ionized species. It was demonstrated that the relative contributions of the ionized and un-ionized species to the total flux, as well as the total flux, vary significantly, depending on the pH of the drug solution in the donor cell. This may provide a means of controlling the flux of these and similar compounds through human skin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502479     DOI: 10.1002/jps.2600731006

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

Review 1.  The barrier function of the skin in relation to percutaneous absorption of drugs.

Authors:  J W Wiechers
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

2.  Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application.

Authors:  P Singh; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

3.  Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil.

Authors:  S D Roy; G L Flynn
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

4.  Percutaneous absorption of nicardipine and ketorolac in rhesus monkeys.

Authors:  D Yu; L M Sanders; G W Davidson; M J Marvin; T Ling
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

5.  Valence topological charge-transfer indices for dipole moments: percutaneous enhancers.

Authors:  Francisco Torrens
Journal:  Molecules       Date:  2004-12-31       Impact factor: 4.411

6.  Development of lapachol topical formulation: anti-inflammatory study of a selected formulation.

Authors:  Ana Amélia M Lira; Elizângela A Sester; André Luis M Carvalho; Ruth R Strattmann; Miracy M Albuquerque; Almir G Wanderley; Davi P Santana
Journal:  AAPS PharmSciTech       Date:  2008-01-25       Impact factor: 3.246

7.  Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil.

Authors:  S D Roy; G L Flynn
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 8.  Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery.

Authors:  Eliana B Souto; Joana F Fangueiro; Ana R Fernandes; Amanda Cano; Elena Sanchez-Lopez; Maria L Garcia; Patrícia Severino; Maria O Paganelli; Marco V Chaud; Amélia M Silva
Journal:  Heliyon       Date:  2022-02-11

9.  Reconstructed Human Epidermis: An Alternative Approach for In Vitro Bioequivalence Testing of Topical Products.

Authors:  Ana Sofia Agonia; Ana Palmeira-de-Oliveira; Catarina Cardoso; Cátia Augusto; Christian Pellevoisin; Christelle Videau; Ricardo Jorge Dinis-Oliveira; Rita Palmeira-de-Oliveira
Journal:  Pharmaceutics       Date:  2022-07-26       Impact factor: 6.525

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.